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The clinical setting, precipitating factors, electrocardio-
graphic features and response to treatment of 32 patients
with torsade de pointes were reviewed. Thirty-one pa-
tients had underlying cardiac disease and 30 patients
had a previous underlying cardiac arrhythmia. Antiar-
rhythmic medications, often in association with electro-
lyte abnormalities (such as hypokalemia and hypo-
magnesemia) were the most common precipitating factors.
In 22 of 26 patients, the serum drug levels of the an-
tiarrhythmic agents were found to be within the thera-
peutic range. However, before the administration ofagents
known to prolong the QT interval, 20 of the 32 patients
had, either alone or in combination, baseline prolon-
gation of the QT interval, hypokalemia or hypomag-
Torsade de pointes is a distinct form of ventricular tach-
yarrhythmia (1-3). It is an irregular, wide QRS complex
arrhythmia of varying rate in which the QRS complexes
twist around the isoelectric line with irregular beat to beat
cycle lengths (2-4). It is often initiated by a premature
ventricular beat with a long coupling interval, so that the
premature ventricular beat occurs on the T wave of the
preceding beat (2-4). It may be self-terminating or may
degenerate into ventricular fibrillation. Torsade de pointes
occurs in the setting of QT interval prolongation which may
be an inherited abnormality (5-8), but is usually caused by
drugs (9-23), electrolyte abnormalities (24-28), intracran-
ial diseases (29,30), toxins (31) or extreme dieting (32).
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nesemia. Ail patients had QTc interval prolongation (mean
0.59 second) immediately before the development of tor-
sade de pointes. Marked lability of T wave morphology
was frequently noted. Cardiac pacing was the only con-
sistently effective mode of therapy.
A characteristic long-short ventricular cycle length
as the initiating sequence was found in 41 of 44 episodes
of torsade de pointes. Reported data support the high
frequency of this electrocardiographic feature of torsade
de pointes in which its onset could be analyzed. It is
suggested that this electrocardiographic characteristic
will aid in both establishing the diagnosis of torsade de
pointes and distinguishing it from other polymorphic
forms of ventricular tachycardia.
Whether polymorphic ventricular tachyarrhythmias associ-
ated with a normal QT interval should be included in this
group has been a matter of controversy (33-35), although
it is generally agreed that the distinction between those
arrhythmias associated with a long and a normal QT interval
probably has important clinical value (3,33.34).
This study consists of the analysis of 61 episodes of
torsade de pointes in 32 patients, and to our knowledge,
is the largest single series of patients with this arrhythmia
reported to date. All cases were associated with prolongation
of the corrected QT interval (QTc ) ' Analysis included de-
termination of the clinical setting, the precipitating factors,
the electrocardiographic features and the response to treat-
ment of this arrhythmia. This analysis and a review of pre-
viously published cases allowed us to recognize a charac-
teristic long-short ventricular cycle length sequence that
precedes the onset of torsade de pointes in the vast majority
of cases. We propose that this is an important feature of
torsade de pointes that not only may help to establish its
diagnosis, but also may assist in its treatment. Furthermore,
rather than being on "atypical ventricular tachycardia" (4),
torsade de pointes has a characteristic initiating sequence,
morphology, clinical setting and response to therapy that
distinguishes it as a distinct type of ventricular arrhythmia.
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Methods
Study patients. The records of the 32 patients included
in this report were taken from the files of the Cardiac Ar-
rhythmia Consultation Service at the University of Alabama
in Birmingham from 1976 to 1982. All were in-patients at
the University Hospital, Birmingham Veterans Administra-
tion Hospital or Cooper Green Hospital. All 32 had clinical
record s and electrocardiographic recordings demonstrating
torsade de pointes available for review by us. The group
had a total of 61 episodes of torsade de pointes .
Electrocardiographic measurements. All patients had:
1) a wide QRS complex tachycardia in which the peaks of
the QRS complexes twisted above and below the isoelectric
line; and 2) a prolonged QTc interval , defined as an interval
greater than or equal to 0.45 second (36). The QT interval
was measured in the limb leads and the QTc interval was
calculated using Bazett ' s rule (QT interval in seconds di-
vided by the square root of the preceding RR interval in
seconds) (37). U waves were not included in the measure-
ment of the QT interval.
Measurements were made from electrocardiographic
tracing s immediately before the onset of torsade de pointes
and from tracings available when the patient was not taking
cardiac medication associated with prolongation of the QT
interval at a time when other ostensibly precipitating factors
had been corrected . The presence or absence of the "R on
T" phenomenon was noted and recorded for all available
tracings demonstrating the initiation of torsade de pointes .
The rate of torsade de pointes was calculated by averaging
the cycle length for all beats in a 6 second interval. When
the duration of the arrhythmia was less than 6 seconds , all
beats were averaged. The presence or absence of beat to
beat regularity of the QRS complexes was noted. All trac-
ings demonstrating the beginning of the torsade de pointes
were analyzed for the pattern of initiation of the arrhythmia,
and the coupling interval of the initiating premature ven-
tricular beat was measured .
Medications and dosages. These were ascertained for
all patients. Drug levels and serum electrolyte values from
the day that torsade de pointes occurred were recorded.
Quinidine serum concentrations were measured by one of
two methods: direct quinidine serum concentrations (mea-
surement of quinidine and its metabolites) were measured
by a fluorometric method; extractable quinidine serum con-
centrations (measurements of only quinidine) were mea-
sured by quantit ative enzyme immunoassay (Emit assay kit ,
Syva Corporation). Disopyramide, n-acetyl procainamide
(NAPA) and procainamide serum concentrations were also
measured by quantitative enzyme immunoassay (Emit). Di-
goxin serum concentrations were measured by radioimmuno-
assay .
Evaluation of treatment. The therapeutic modalities used
in treatment of torsade de pointes were recorded and their
effectiveness in suppressing recurrence of the arrhythmia
was determined . If torsade de pointes recurred while the
patient was receiving a specific treatment, that treatment
was listed as "not effective." Iftorsade de pointes did not
recur during the period of treatment, the treatment was listed
as " effective." Only patients who died as a direct result of
torsade de pointes, rather than from complications of their
underly ing disease. were recorded as dying from torsade de
pointes .
Results
Clinical Features
The age , sex, card iac diagnosis , underlying arrhythmia,
electrolyte values, medications and apparent precipitating
factors for torsade de pointes are listed in Table 1. The mean
patient age was 58.1 years (range 28 to 79). There were 16
men and 16 women. Twenty-four of the 32 patients had
manifest conge stive heart failure.
Cardiac diagnoses. The most common underlying car-
diac disorder was ischemic heart disease (17 patients). The
five patients with rheumatic heart disease all had atrial fi-
brillation and were taking digoxin and quinidine or a quin-
idine-like antiarrhythmic drug. Cardiomyopathy was present
in four patients . Three patients had a diagnosis of sick sinus
syndrome, and two of these patients also had ischemic heart
disease. One patient each had presumed viral myocardit is,
Marfan ' s syndrome with ascending aortic aneurysm and
aortic regurgitation, Ebstein 's anomaly and the congenitally
prolonged QT syndrome. Only one patient had no apparent
underlying cardiac disease.
Underlying arrhythmias. Thirty of the 32 patients had
an underlying cardiac arrhythmia. Ten patients had atrial
fibrillation alone , 6 had premature ventricular beats alone
and 9 had recurrent, monomorphic ventricular tachycardia,
defined as three or more consecutive premature ventricular
beats. Four patients had two underlying arrhythmias: one
patient with the Wolff-Parkinson-White syndrome had re-
current atrioventricular junctional reciprocating tachycardia
and atrial flutter , two patients had atrial fibrillation and
premature ventricular beats and one patient had atrial fi-
brillation and ventricular tachycardia. One patient had re-
current syncope for 38 years and was diagnosed as having
the congenitally prolonged QT syndrome after torsade de
pointes was recognized on a Holter monitor recording. Two
patients had no known underlying cardiac arrhythmias .
Factors Precipitating Torsade de Pointes (Table J)
Medications. Of the medications implicated in precip-
itating torsade de pointes , quinidine was the most common .
Nineteen patients were taking quinidine, 16 in the form of
quinidine sulfate and 3 in the form of quinidine gluconate .
Two patients were taking quinidine sulfate in combination
with another medication, one with mexiletine and one with
00
Table 1. Summary of Clinical Data in 32 Cases 000
Electrolytes
(K = meq/liter),
Age (yr) Cardiac Underlying (Ca + + = rng/dl) , Apparent Precipitating CJ:>':
Case & Sex Diagnosis Drugs Drug Levels* Arrhythmia (Mg + + = mg/dl) Factors of TdP ;o;!>en-<
;!>tTl
52F Myocarditis, Amiodarone, 600 mg/day; Digoxin, 1.0 mg/rnl; A. fib, K+ ,3.6; Amiodarone, o-l
tTl;!>
MVP, CHF digoxin, 0.25 mg/day amiodarone, N.A. PVCs Ca+ + ,9.2; hypomagnesemia or-
Mg+ +,2.0
tTl
-0
0
2 62M IHD, Quinidine gluconate, 1.45 Quinidine (extract), 7.0 A. fib K+,2.7; Quiniding gluconate, Z-l
SIP MI, g/day; digoxin, 0.125 mg/liter; digoxin, 3.0 Ca+ + ,9.1; hypomagnesemia, tTlen
CHF mg/day mg/ml Mg+ +,1.9 hypokalemia
3 64F RHD-MR, Quindine sulfate, 1 g/day, Quinidine (direct), 5.1 A. fib, K+,4.01; Quinidine sulfate
CHF digoxin, 0.25 mg/day mg/liter; digoxin, 3.0 PVCs Ca+ + ,9.2;
mg/ml Mg+ +,N.A.
4 46F RHD-MS, SIP Disopyramide, 600 Disopyramide, 1.8 J,Lg/ml; A. fib K+,41; Disopyramide,
MVR mg/day; digoxin, 0.25 digoxin, I. I mg/ml Ca+ + ,9.9; hypomagnesemia
mg/day Mg+ +,1.7
5 63M IHD, Quinidine sulfate; 1.2 Digoxin, I 5 mg/ml; PVCs K+,3.0; Quinidine sulfate,
HTN, CHF, g/day; digoxin, 0.125 quinidine, N.A. Ca+ + ,9.2; hypokalemia
hypothyroid rng/day Mg+ +,N.A.
6 54M ETOH CM, Quinidine sulfate, 1.2 Quinidine (direct), 11.1 PVCs K+,3.1; Quinidine sulfate,
CHF g/day; digoxin, 0.125 mg/liter; digoxin, 1.0 Ca+ +,8.5; hypokalemia
mg/day mg/ml Mg+ +,2.2
7 60M Congenital Quinidine sulfate, 1.2 Quinidine (extract), 3.0 "Syncope" K+,3.6; Congenital long QT,
long QT g/day mg/liter Ca+ +,8.6; quinidine sulfate,
Mg+ +,2.0 hypomagnesemia
8 65M IHD, Quinidine sulfate, 1.6 Quuudine (extract), 6.0 VT K+,3.9; Quinidine sulfate
S/PMI, g/day; digoxin, 0.125 mg/hter: digoxin, I.7 Ca++,9.4,
CHF mg/day mg/ml Mg+ +,N.A.
9 66F IHD, SSS Disopyranude, 600 Disopyramide , 2.3 mcg/ml PVCs K+ ,4.2; Disopyrarnide
mg/day Ca+ +,9.6;
Mg+ +,N.A.
10 28F Penpartum, Amiodarone, I g/day, Digoxin 0.7, mg/ml; VT K+ ,4.1; Arnrodarone,
CM procainamide, 3 g/day; procainarmde, 7.4 Ca+ +,10.2; procainarmde
digoxin. 0.125 mg/day rng/liter; NAPA, 4.5 Mg+ +,N A.
mg/liter; amiodarone, N.A.
II 64M IHD, Quinidine sulfate, I 6 Quinidine (extract), 2.2 VT K+ ,3.1; Quinidine sulfate, zHTN, g/day; digoxin, 0.125 mg/liter; digoxm, 0.6 Ca+ + ,8.7; hypokalemia 0<: '-
CHF mg/day; phenytoin, 300 mg/rnl; phenytoin. 4.2 " ;!>Mg+ +,N.A. 3 o
?inmg/day mcg/ml :.<
'0:2-12 74F IHD, SIP MI Propranolol, 400 rng/day N.A. None K+ ,4.5; RCA injection of
00 .
~N
X2 Ca+ + ,9.8; contrast medium
00 •
Oz
Mg+ +,N.A.
T'o
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Table 1. Summary of Clinical Data in 32 Cases (continued)
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Electrolytes
:<;N
00 '
""'z(K = mcq /l iter ), 000
Age (yr ) Cardiac Unde rlymg (Ca + + = mg/d l), Apparent Prccipit aring ~ ~
Case & Se x Diagnosis Drugs Dru g Level s* Arrh ythmia (Mg + + = mg/dl ) Factor s of TdP -.I
13 48F RHD . Procamarmde . 3 g/day , Procarnarrude , 5 .2 mg/lu cr; A . fib K +,4 5; Proc ainarmd e
MS -MR. digoxin, 0 .25 mg/day digoxin . N .A Ca+ +.9 6 ;
HTN. CH F Mg+ +. N. A .
14 55M Marfans AR . Procainarmde , 3 g/day; Procamarmde , 2 .9 mg/lit er ; A . fib K+.33 ; Proca inanude ,
C HF digoxin . 0 25 rug/day; digoxin . N.A ; lidoca ine. Ca+ + .9 .6 ; hypokalemi a
lidocaine. 3 rng/rnin N A . Mg + +.N.A.
15 33M IHD . SIP Ml. Procainarmd e , 3 g/day: Disop yram ide, 2 .4 IJ,g/ml . PYCs K + ,4.6; Procainamid e ,
CHF disopyrarmde , 600 procamamide , N .A Ca + + .IO.O, drsop yramide
rug /day Mg + + .N.A
16 60M ldiopath CM . Quirudine sulfate , 600 N A. A . fib K +,4 4; Quinidine sulfate
CHF mg/day : digoxin, 0.25 Ca+ + .9 .7 ;
rug/day Mg+ +.N A
17 54F RHD. MR. Quinidine sulfate , 1.3 Quuudrn e (d irec t) . 5 .3 A fib K + ,4 .0 ; Qumidine sulfate
HTN g/day; d igoxm . 0 25 rng/htcr, digoxin . N.A Ca+ + .9 .5.
rng/da y Mg + + .N.A .
18 54F RHD. AR. Procamarmde, 1.5 g/day ; Procainarmde, 4. 0 mg/li ter , A . fib K + ,4 3. Procainarmd e,
MR . TR . digoxm , 0 .25 rug/da y d igoxr n . 1.2 mg/ml Ca+ + ,8 6; quinidine sulfate
CHF Mg+ + ,2 .3
19 73 F IHD . SIP Ml. Qu inidine gluconate , 990 Quimdme (drre c t) , 2 .6 A fib K + ,4 .1 ; Quinidmc gluconate
CHF rug/day: digoxin . 0.1 25 mg/li ter : digoxin . I 0 Ca+ + ,9.4 ,
rug/day mg/m l Mg+ + .N.A .
20 57F Ebsterns CHB Quinidine sulfate , I 2 Qurrudine (direct) , 4 .6 A . lib. VT K+ .4.4. Quinidine sulfate,
g/day; digoxm. 0 .25. mg/Iiter; digoxin . 0 .5 Ca+ + .9 .5 ; hyp omagnesemia
rng/day 109/Ill I Mg++ .2. 1
2 1 73F IHD , SIP Ml. Quinidine sulfate. 800 Qu imdine (ex trac t) , 3 .2 YT K+ ,3 .6 ; Qu inidine sulfate
SS S. C HF . rug/day mg/hter Ca + + , I 1.0.
CRF Mg + + ,2.8
....,
0
'"22 61M IHD . SIP Ml. Quirudine sulfate . 800 Quirudme (ex trac t) , I 6 PYC , K + ,4.4; Quinidine sulfate '">
C HF. HT N rug /day rug/liter Ca + + . 10 3; 0rrt
Mg+ + ,N .A . 0:>::m>
"C-<
23 68M IHD . HTN. Qumidine sulfate, 1.2 Qu inid ine . 2 .0 mg/Iiter YT K+.N A. ; Quirudmc sulfate Q~
CHF g/day Ca+ + .N .A .; z...., ;..
Mg+ + .N .A . rn r
24 34M IHD . MI. Qu irudme sulfate , 800 Qu inidmc (direc t) , 5 2 PYC s K+.4 I ; Quinidin e sulfate,
HTN . CH F mg/day ; digox in 0 .25. mg/htcr: dr goxm , 0 .9 Ca+ + .8.6 ; hypom agnesem ia
mg/day mg/m l Mg+ + .2. 1 00s
Table 1. Summary of Clinical Data in 32 Cases (continued)
00-o
Age (yr)
Case & Sex
25 45F
26 64F
27 73M
28 67F
29 79F
30 73M
3 1
32
48M
5 1M
Cardiac
Diagnosis Drugs Drug Leve ls*
None Thio ridazi ne, 200 mg/day N.A .
Hypert rophi c , Quinidine sulfate, 800 Quinidi ne (direct) , 7 .9
CM, WPW mg/day rug/liter : digoxin , 1.4
mg/ml
tHD , CHF, Procai narrude , 1.5 g/day ; Procainarnidc , 2 .8 mg/liter ;
CRF digoxin, 0 . 125 mg/day NAPA, 22.3 mg/liter ;
digox in, 2 .0 mg/rnl
AMI, CHF, Digoxin, 0 . 125 rug/day: Digoxin , 0 .2 mg/ml ;
HT N lidocaine , 4 mg/min; lidocaine. 7 .2 ILg/ml;
procainamide , 3 g/day procainarnidc , N.A.
SSS QUinidine gluconate , 972 QUinidine (direct), 3 .3
mg/day; digox in, 0 .25 rug/liter : digoxin , N.A.
mg/day
IHD , SIP MI, Quinidine sulfate , 900 Quinidine (direct), 2 .8
CHF mg/day ; digoxin, 0. 25 mg/liter ; digoxi n, 1.2
mg/day; rnexiletine, mg/ml ; mexi lctine , N.A .
900 mg/day
AMI , HTN , Digox in. 0 .25 rug/day; DIgoxin, 0 .7 mg/ml ;
CHF mex ilet ine , 900 rug/day rnexilct inc , N.A.
IHD, SIP MI, Quinidin e sulfate, 800 Quindine (extract) , 1.2
CHF mg/day : digox in 0. 25, mg/h ter; digoxin , 1.3
mg/day mg/ml
Unde rly ing
Arrhythmia
None
A. flutter ,
SVT
A. fib
VT
A. fib
VT
VT
VT
Electrolytes
(K = rneq/liter),
(Ca + + = rng/dl ) ,
(Mg + + = mg/dl )
K + ,3.5;
Ca+ + .8 .7 ;
Mg + +, 1.3
K + ,3.7 ;
Ca + + ,N.A.;
Mg + +,N.A .
K + ,N.A.;
Ca+ +,N.A, ;
Mg + + ,N .A.
K + ,3 .9;
Ca+ + ,8 .3;
Mg + +,N.A.
K + ,4 .3;
Ca+ + ,8 .6;
Mg + + , 1.9
K + ,4 .3;
Ca + + ,8 .8 ;
Mg + +,N.A .
K+ ,3.7 ;
Ca + + ,9 9 ;
Mg + +,N .A .
K+,4 . I;
Ca+ + ,9 .5 ;
Mg + + ,N .A.
Apparent Precipitating
Factors of TdP
Thio ridaz ine,
hypomagnesemia
Quin idine sulfate
Proca inamide
Procainamidc ,
hypocalcemia
Q uinidine gluco nate ,
hypomagnesem ia
Hypokalemia,
qu inidine sulfate,
Mexilet ine
Mex iletine
Quinidine sulfate
-l;':
O;l>
~ -<
E;~
l'T1 ;l>
or-
l'T1
25z
-l
l'T1
'"
*T herapeutic drug levels: digoxin = 0.5 to 2 .2 mg/ml; disopyramide = 2 to 5 ILg/ml ; lidocaine = 1.5 to 6 lLg/m l, NAPA + procainarnide
less than 25 rng/liter; phenytoin = 4 to 20 ILg/ml; proca inarrude = 4 to 8 ILglliter ; quinidine (direc t) = 3 to 6 mgll iter; quinidine (extractable) = 2 to 5 mg/liter.
A. fib = atrial fibnllation; AMI = acute myocardial infarction; A. Flutter = atn al nutter; AR = aortic regurgitation ; CHB = complete heart block ; CHF = congestive
heart fai lure; CM = cardiomyopat hy; CRF = chro nic renal failure; ETOH = alcoholic; HTN = hypertension ; IHD = ischemic heart disease. MR = mitral regurgitation ;
MS = mitral stenosis, MVP = mitral va lve pro lapse ; N.A . = not available; NAPA = n-acetyl procai namide; RCA = nght coro nary artery; RHD = rheumatic heart
disease; SIP MI = status post-myocard ial infarct ion ; SIP MVR = status post-mitral valve replacement ; SSS = sick sinus syndrome; SVT = supraventricular tachycardi a;
TdP = torsade de pointes; TR = tricuspid regurgitatio n; VT = ventn cular tachycardia ; WPW = Wolff-Parkinson-Whuc syndrome.
~~
" ;l>3 o
g" n
~ <
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phenytoin. Seven patients were receiving procainamide, five
as the only antiarrhythmic drug, one in combination with
disopyramide and one in combination with amiodarone. Di-
sopyramide was the only antiarrhythmic agent in two pa-
tients, mexiletine in one patient and amiodarone in one
patient. One patient was receiving thioridazine.
In one patient (Case 12), the development of torsade de
pointes did not appear to be associated in any way with the
administration of medication. She was a 70 year old woman
with ischemic heart disease who had had two previous myo-
cardial infarctions and unstable angina for 2 weeks prior to
admission. She developed torsade de pointes in the cardiac
catheterization laboratory when angiographic contrast me-
dium (Renografin-75) was injected into the right coronary
artery. Her only medication was propranolol, 100 mg orally
every 6 hours, but her QTc interval immediately before the
development of torsade de pointes was prolonged to 0.55
second.
Serum drug levels. Drug levels and their respective
therapeutic ranges for our laboratory are listed in Table 1.
Quinidine levels were measured in 17 of the 19 patients
receiving the drug. Only three patients had levels exceeding
the so-called therapeutic range. Procainamide levels were
measured in six of the eight patients receiving this drug.
Three of these patients also had concomitant n-acetyl pro-
cainamide (NAPA) levels measured. Five of these six pa-
tients had serum levels that did not exceed the therapeutic
range. One patient with chronic renal insufficiency had a
procainamide serum level of 2.8 mg/liter with a combined
procainamide and NAPA serum level of 25.1 mg/liter (ther-
apeutic range for procainamide plus NAPA < 25 mg/liter).
Serum levels were measured in the three patients receiving
disopyramide and none exceeded the therapeutic range.
Electrolyte abnormalities. Six patients had a serum po-
tassium concentration less than 3.5 mEq/liter. One patient
had been taking quinidine gluconate, 1.45 g/day, for several
years but developed torsade de pointes only when he became
hypokalemic (2.7 mEq/liter). After correction of his hy-
pokalemia, the patient was discharged on the same dose of
quinidine gluconate without further arrhythmia. Six patients
had serum potassium concentrations in the range of 3.5 to
3.7 mEq/liter, perhaps reflecting total body potassium de-
pletion. Eight of 11 patients in whom the serum magnesium
concentration was measured had hypomagnesemia (normal
range 2.2 to 3.0 mg/dl), the level being as low as 1.3 mg/dl.
Electrocardiographic Data (Table 2)
QT intervals. The baseline electrocardiograms showed
a mean QT interval of 0.39 second and a mean QTc interval
of 0.45 second. The baseline QTc interval was greater than
0.45 second in 14 patients, all but 1 of whom subsequently
received a drug known to prolong the QT interval. The one
patient (Case 12) who did not receive such a drug did undergo
a procedure (angiographic dye injection of the right coronary
artery) known to prolong the QTc interval (38-41). Fur-
thermore, three patients had baseline QTc interval prolon-
gation in association with QRS interval prolongation due to
the presence of right (Case 23) or left (Cases 6 and 32)
bundle branch block, a complicating factor. Nevertheless,
these three patients exhibited classic torsade de pointes in
association with clear prolongation of the QTc interval (0.64,
0.60 and 0.52 second, respectively).
The electrocardiograms recorded immediately before the
development of torsade de pointes showed a mean QT in-
terval of 0.54 second and mean QTc interval of 0.59 second.
In one patient (Case 7) who had the congenitally prolonged
QT interval syndrome, the electrocardiogram. in the absence
of cardiac medications, showed a QTc interval of 0.42 sec-
ond in the supine position. When the patient stood up, the
QTc interval increased to 0.66 second.
The duration of ventricular repolarization, as evidenced
by the QT interval, was frequently noted to be labile. Salvos
of premature ventricular complexes frequently were pre-
ceded by a progressive lengthening of the QT interval and
a change in the configuration of the T wave (Fig. 1).
Long-short initiating ventricular cycle length. Torsade
de pointes was preceded regularly by ventricular beats ex-
hibiting a long-short cycle length (Fig. 2 and 3). The first
ventricular complex of the sequence was composed of a
premature ventricular beat or the last beat of a salvo of
premature ventricular beats. This was followed by a pause
and a subsequent supraventricular beat. Then, a premature
ventricular beat occurred after the supraventricular beat at
a relatively short cycle length and precipitated the torsade
de pointes. This long-short ventricular cycle length sequence
preceded torsade de pointes in 41 of 44 episodes in which
the beginning of the arrhythmia was recorded. This long-
short cycle length sequence did not precede the onset of
torsade de pointes in only three instances.
Coupling intervals. The average coupling interval of
each initiating premature ventricular beat was 0.49 second
(range 0.27 to 0.88) (Table 3). The initiating premature
ventricular beat occurred during the T wave (R on T phe-
nomenon) in 38 of 44 episodes in which the beginning of
torsade de pointes was recorded and available for our re-
view. In six episodes, the initiating premature ventricular
beat occurred after the end of the T wave.
Repetitive short runs of polymorphic ventricular tachy-
cardia frequently preceded the onset of torsade de pointes.
The average rate of torsade de pointes was 227 beats/min
(range 170 to 300). The beat to beat cycle length of the
ventricular tachycardia was irregular in all instances.
Treatment of Torsade de Pointes (Table 4)
The response to therapy of torsade de pointes is sum-
marized in Table 4. Direct current cardioversion, drug
administration and ventricular and atrial pacing were among
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Table 2. Electrocardiographic Findings
Electrocardiogram Before
Baseline Electrocardiogram Torsade de Pomtes
Interval Interval
Drug and HR
(seconds)
HR
(seconds)
Case Dose Rhythm (beats/min) QRS QT QT, Rhythm (beats/min) QRS QT QTc
I Amiodarone, 600 mg/day Sinus 92 008 OAO 050 Sinus 46 0,08 0,76 0,68
2 Quinidine gluconate, IA5 Sinus 98 0.10 OAO 0,51 Sinus 69 0.14 0,66 0.71
g/day
3 Quirndine sulfate, 1.0 g/day N.A, N,A. N,A. N.A. N,A. A fib 71 0,12 0,60 0.63
4 Disopyramide, 600 mg/day A. fib 91 0.08 0.36 OA4 Sinus 65 0.10 0.60 0.62
5 Quinidine sulfate, 1.6 g/day Sinus 90 0.08 0.38 OA8 Sinus 90 0.08 0.50 0.63
6 Quinidine sulfate, 1.2 g/day Sinus 95 0.16 OA2 0.53 Sinus 71 0.16 0.60 0.64
7 Quinidine sulfate, 1.2 g/day Sinus 48 0.06 046 OA2 Sinus 66 0.06 0.58 0.62
(supine)
Smus 68 0.06 0.62 0.66
(standing)
8 Quinidine sulfate, 1.6 g/day N.A. N.A. N.A. N.A. N.A. Sinus 80 0.10 OA4 0.52
9 Disopyramide, 600 mg/day Sinus 90 0.10 OAO 0.50 Sinus 70 0,08 0.64 0.68
10 Amiodarone, I g/day; Sinus 94 0.08 0.34 OA3 Smus 81 0.10 OA4 0.51
procainamide 3 g/day
II Quinidine sulfate, 1.6 g/day Sinus 58 0.08 OA2 042 Sinus 47 0.08 0.72 0.64
12 None Sinus 74 0.06 OAO OA5 Sinus 94 0.08 OA4 055
13 Procainamide, 3 g/day A. fib 95 0.08 0.32 OA8 Sinus 43 008 0,60 0.51
14 Procainamide, 3 g/day Sinus 59 0.10 OAO OAO Sinus 68 0.10 052 0.55
15 Disopyramide, 600 mg/day Sinus 58 0.12 OA8 OA8 A. paced 100 0.08 OAO 0.52
16 Quinidine sulfate, 600 mg/day A. fib 100 0.08 0.32 OAI Sinus 54 0.10 0.68 0.64
17 Quirudine sulfate, 1.5 g/day A. fib 92 0.06 0.36 OA5 Smus 66 0.10 0.60 0,63
18 Procainamide, 1.5 g/day A. fib 80 0.06 0.32 0.37 A. fib 103 0.08 0.38 0.50
19 Quinidine gluconate, 990 A. fib 98 0.08 0.30 039 A. fib 56 0.12 0.56 054
mg/day
20 Quuudine sulfate, 1.2 g/day Sinus 60 0.12 OAO OAO Sinus 68 0.12 0.64 0.68
21 Quinidine sulfate, 800 mg/day Sinus 82 0,08 OAO OA7 Sinus 122 0.08 OA8 0.69
22 Quinidine sulfate, 1.6 g/day Sinus 90 0.06 0.34 OA2 Sinus 90 0.06 OAO 0.49
23 Quinidine sulfate, 1.2 g/day Sinus 78 0.12 OA4 0.50 Sinus 68 0.12 0.56 0.60
24 Quinidine sulfate, 800 mg/day Sinus 115 0.10 0.34 OA7 Sinus 115 0.08 0,34 047
25 Thioridazine Sinus 83 0.06 OA9 0.58 Sinus 68 0.08 OA4 OA7
26 Quinidine sulfate, 800 mg/day N.A. N.A N.A. N.A. N.A. Sinus 54 008 0.84 0.79
27 Procainarmde, 1.5 g/day N.A. N.A, N.A N A. N.A. A. fib 72 0.08 OA8 0.53
28 Procamarnide, 3 g/day Sinus 94 0.09 0.36 OA5 Sinus 88 0.11 0.56 0.68
29 Quinidme gluconate, 972 V paced 72 0,16 OAO 044 Sinus 81 0,06 0.60 0.70
mg/day
30 Mexiletme, 900 rng/day; Sinus 65 0.10 OA4 OA5 Sinus 73 0.10 0.54 0.60
quirndme sulfate, 900
rng/day
31 Mexileune, 900 mg/day Sinus 79 0.08 OAO OA6 Sinus 83 0.08 OAO OA7
32 Quinidine sulfate, 800 mg/day Sinus 84 0.14 0.39 OA6 Sinus 76 0.14 OA6 052
HR = heart rate, V = ventricular; other abbreviations as in Table I.
the treatments used. Most patients received more than one recurred during treatment with bretylium and lidocaine in
type of treatment. three patients and was suppressed in two patients. Phenytoin
Direct current cardioversion. This was used in 19 pa- was used as the sole therapy in two patients and was effective
tients. In each case, it was at least transiently effective in in one. Phenytoin used in combination with lidocaine was
terminating torsade de pointes. effective in three of five patients. Isoproterenol was used
Drug therapy. Lidocaine was the most common an- alone in one patient with the congenitally prolonged QT
tiarrhythmic medication used in an attempt to suppress tor- interval syndrome, but it precipitated torsade de pointes
sade de pointes. Used alone in 19 patients, lidocaine ef- (42), Isoproterenol was used in combination with lidocaine
fectively suppressed torsade de pointes in 9 patients, but in in four patients and was effective in two.
10 patients the arrhythmia recurred. Bretylium was used in Temporary pacing. This was the only consistently ef-
combination with lidocaine in five patients. Torsade de pointes fective therapy. In six patients, endocardial ventricular pac-
lACC Vol. 2, No 5
November 1983:806-17
KAY ET AL.
TORSADE DE POINTES
813
Figure 1. Patient 17, Electrocardiographic tracings are not con-
tinuous. Upper tracing: The representative example of labile T
wave configuration and marked QT interval prolongation. Note
further prolongation of the QT interval after a long precedingRR
interval(4th complex).Lower tracing: QT prolongation anddeep-
ening of the T wave following a postextrasystolic pause (3rd com-
plex). Note the run of nonsustained ventricular tachycardia pre-
cipitated by a premature ventricular beat with a long coupling
interval.
ing at rates from 80 to 100 beats/min suppressed the ar-
rhythmia. In all six, prior drug therapy had failed to suppress
torsade de pointes. Two patients who had torsade de pointes
after cardiac surgery were successfully treated with atrial
pacing using temporarily placed epicardial electrodes.
Mortality
Five patients in this series died as a direct result of torsade
de pointes. One patient died with intractable torsade de
pointes that was unrecognized and was treated with pro-
cainamide. Four patients died as a result of severe anoxic
brain damage that resulted from episodes of torsade de pointes.
Discussion
Our observations of the clinical setting and manifesta-
tions of torsade de pointes confirm most previously pub-
lished observations in smaller patient series. However, anal-
Figure 2. Patient 17. Electrocardiographic tracings are not con-
tinuous. Upper tracing: Initiationoftorsade de pointes.Premature
ventricular beat (2nd complex) is followed by a compensatory
pause that is ended by a supraventricular beat, forming the "long"
cycle length of the initiating sequence. A premature ventricular
beat (4th complex) initiates torsade de pointes, forming the "short"
cycle length of the initiating sequence. Lower tracing: Termi-
nationof a 70 secondepisodeof torsadede pointeswithprogressive
shorteningof the QT interval and evolution of T wave changes.
.j-, '
Figure 3. Patient 19. Continuous tracings. A long-short ventric-
ular cycle length sequenceconsisting of a postextrasystolic pause
and a premature ventricular beat occurring on the apex of the T
wave (4th complex) initiates torsade de pointes.
ysis of this large series brings several aspects into sharper
focus. In addition, several observations are new, deserve
emphasis and have important therapeutic implications.
Characteristics of Torsade de Pointes
The long-short initiation cycle length. Our observa-
tion that the ventricular beats immediately preceding the
onset of torsade de pointes exhibited a long-short cycle
length sequence in the vast majority of the patients in this
series appears to be a newly appreciated and important
additional feature of this arrhythmia. A review of previously
published electrocardiographic examples of torsade de
pointes (5,6,9,11-13,15,17,18,21,22,25-27,30,31,43-67)
in which the initiating ventricular complexes are provided
demonstrate that this long-short sequence also was present
in the great majority of cases. Only 3 of the 44 episodes of
torsade de pointes in our series did not have this common
initiating sequence. When our cases are combined with pre-
viously reported examples of torsade de pointes only 16
(12.2%) of 131 lack this characteristic. We suggest that this
electrocardiographic feature will aid in the accurate diag-
nosis oftorsade de pointes associated with QTc prolongation
and help distinguish it from other polymorphic ventricular
tachycardias. It is interesting that in the controversial series
of patients with polymorphic ventricular tachycardia and
normal QTc intervals reported as torsade de pointes by Ho-
rowitz et al. (35), all illustrated examples lack this long-
short sequence.
Electrolyte abnormalities. Both hypokalemia and hy-
pomagnesemia are known to prolong the QT interval (24-28).
A striking number of patients had either hypokalemia or
hypomagnesemia, or both, and several had relatively low
(3.5 to 3.7 mEqlliters) potassium levels, suggesting that
total body potassium may have been depleted. Although the
association of hypokalemia and torsade de pointes is well
recognized, the possible role of hypomagnesemia may be
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Table 3. Characteristics of Torsade de Pointes
Initiatmg PVC Irregular Beat to
Long-Short Coupling Interval HR Beat Cycle
Case Initiating Cycle (seconds) "R on T" (beats/mm) Length
I Yes 0.66 Yes 230 Yes
2 N A. N.A. N.A. 240 Yes
3 Yes 0.44 Yes 215 Yes
Yes 0.44 Yes 200 Yes
4 Yes 058 Yes 260 Yes
N.A N.A. N.A. 240 Yes
N.A. N.A. N.A 290 Yes
5 N A. N.A. N.A. 170 Yes
6 Yes 0.46 Yes 190 Yes
Yes 0.49 Yes 170 Yes
7 N A. N.A N A. Yes
8 N.A. N.A. N.A. 215 Yes
9 Yes 0.49 Yes 185 Yes
Yes 0.54 Yes 185 Yes
10 Ye, 0.43 Yes 215 Yes
Ye, 043 Yes 215 Yes
Yes 0.44 Yes 190 Yes
Yes 0.43 Yes 215 Yes
Yes 0.44 Yes 190 Yes
Yes 044 Yes 215 Yes
Yes 0.46 Yes 215 Yes
II N.A. N.A. N.A 250 Yes
12 No 044 No 290 Yes
13 No 0.88 No 215 Yes
Yes 0.60 No 190 Yes
14 N.A. N A. N A. 230 Yes
15 No 034 Yes 240 Yes
N.A. N.A. N.A. 270 Yes
N.A. N.A. N.A 270 Yes
16 Yes 060 Yes 190 Yes
Yes 0.60 Yes 190 Yes
Yes 0.60 Ye, 260 Yes
17 Yes 040 Yes 270 Yes
Yes 0.61 Yes 220 Yes
Yes 0.46 Yes 280 Yes
Yes 0.55 N A. 210 Yes
N.A. NA N.A. 230 Yes
18 Yes 0.48 No 300 Yes
19 Yes 0.46 Yes 230 Yes
20 Yes 0.40 Yes 170 Yes
Yes 0.46 Yes 190 Yes
Yes 0.43 Yes 195 Yes
2\ N A. N A. N A. 230 Yes
22 N.A N.A N.A. 320 Ye,
23 Yes 0.53 Yes 260 Yes
24 N.A. N.A. N.A. 290 Yes
25 Yes 0.27 Yes 285 Yes
Yes 0.27 Yes 260 Yes
26 Ye, 0.56 Yes 260 Ye,
Yes 0.56 Yes 190 Yes
27 N.A. N A. N.A. 200 Yes
28 Yes 0.56 Yes 185 Ye,
N.A N.A. N.A. 210 Yes
Ye, 0.49 Yes 180 Yes
Yes 054 Yes 190 Yes
Yes 0.63 Yes 175 Yes
Yes 0.68 Yes 190 Yes
29 Yes 0.62 No 200 Ye,
30 N.A. N A. N A. 260 Yes
31 Ye, 0.28 Yes 290 Yes
32 Ye, 0.40 No 230 Yes
Abbreviations a, in Tables 1 and 2
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Table 4. Treatment of Torsade de Pointes*
Patients Treatment Treatment
Therapy (no) Effective (no.) Not Effective (no.)
Direct current 19 19 0
cardioversion
Lidocaine (alone) 19 9 10
Lidocame + bretylium 5 2 3
Lidocaine + phenytoin 5 3 2
Lidocaine + isoproterenol 4 2 2
Phenytoin (alone) 2 I I
Isoproterenol (alone) I 0 1
Pacing
Ventricular 6 6 0
Atrial 2 2 0
Total 63 44 19
*Most patients had more than one form of treatment.
underappreciated. This is supported in our series by the failure
to obtain serum magnesium levels in 21 of the 32 patients.
Yet the serum magnesium was low in 8 of the II patients
in whom it was measured. Thus, although the possible role
of hypomagnesemia in precipitating torsade de pointes has
been described (23), our data suggest it may be much more
important than previously thought. This may have contrib-
uted to the increase in the baseline QTc interval in 13 of
the 14 patients in whom it was present (one patient had a
congenitally prolonged QT interval). It also may, in part,
explain why torsade de pointes was present in so many of
these patients despite normal serum levels of antiarrhythmic
drugs.
Pathophysiologic substrate of torsade de pointes. The
asynchronous recovery of excitability in cardiac muscle is
said to be a predisposing factor for reentrant arrhythmias.
The combined factors of underlying QTc interval prolon-
gation due to drug or electrolyte abnormalities, or both, and
a long cycle length following a premature ventricular com-
plex would seem to be conducive to exacerbation of asyn-
chrony of repolarization. Han and Moe (69) demonstrated
temporal dispersion of refractory periods as they recorded
from different sites in the ventricles of anesthetized dogs
during varying experimental conditions. The temporal dis-
persion of refractoriness was increased after a premature
stimulus, left stellate ganglion stimulation, conditions of
myocardial ischemia or hypothermia and after the admin-
istration of quinidine sulfate or toxic dosages of ouabain.
In another study (70), the same group demonstrated that the
temporal dispersion of refractoriness was increased during
pacing at longer cycle lengths. Our observation that a pause
preceding the last supraventricular beat and its coupled pre-
mature ventricular beat frequently initiates torsade de pointes
is likely a manifestation of the very marked temporal dis-
persion of refractoriness that may be expected to occur with
a prolonged QTc interval.
Additional observations in the present and previous stud-
ies are also important in determining the presence of torsade
de pointes. Clark et al. (70) reported T wave aberration after
a postextrasystolic pause as a warning sign preceding torsade
de pointes in a group of seven patients. Labile T wave
configuration with short runs of premature ventricular beats,
pairs of premature ventricular beats and ventricular tachy-
cardia occurred in many of our patients. Several authors
(2,35,71-73) emphasized the relatively long coupling in-
terval of the premature ventricular complex initiating torsade
de pointes. This was a typical sign in our patients also, but
importantly, because of the QT interval prolongation, the
initiating premature ventricular beat occurred simulta-
neously with the T wave (R on T phenomenon) in the great
majority of our cases, a feature that has previously been
emphasized (2,4,72-74).
Keren et al. (43) noted a slow ventricular rate (40 to 65
beats/min) immediately before the onset of torsade de pointes
in all 10 of their patients with this arrhythmia. Bradycardia
was not noted in the majority of our patients. Neither did
we observe the widening of the QRS complex before the
onset oftorsade de pointes that was noted by the same group.
Treatment and Prevention
Drug treatment and temporary cardiac pacing. The
effectiveness of drug treatment of torsade de pointes was
unpredictable. Despite reports of successful treatment with
isoproterenol (34,44,45), we found it to be unreliable in the
few cases in which it was used. In one patient with the
congenital QT interval prolongation syndrome, it was haz-
ardous, a feature previously described (42). In this study,
temporary overdrive atrial or ventricular pacing was effec-
tive in all patients in whom it was used. The success of
increasing the heart rate with cardiac pacing in preventing
torsade de pointes may be due to the known decrease in the
QT interval associated with the increase in heart rate. Also,
and perhaps most important, the faster ventricular rate that
results from cardiac pacing prevents the occurrence of any
long pauses. Therefore, the characteristic initiating long-
short ventricular cycle length sequence is suppressed.
Assessment of serum electrolytes and QTc interval.
Finally, on the basis of analysis of our data, another clinical
caveat seems worth reemphasizing. Before initiating treat-
ment with agents known to prolong the QT interval, it should
be established for each patient that serum potassium and
magnesium levels are normal and that the baseline QTc
interval is not already prolonged. Had this been done for
the patients in this study, one or more of these abnormalities
would have been detected in 20 of the 32 patients, even
though a baseline electrocardiogram and baseline serum po-
tassium and magnesium levels were not available for anal-
ysis in all 32 patients.
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